Clinical trial
A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)
NCT06905509 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)
- Lead sponsor
- University of California, Davis
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 31, 2025
- Completion date
- August 1, 2030
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent diffuse large b-cell lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent high grade b-cell lymphoma with myc and bcl2 rearrangements, recurrent high grade b-cell lymphoma with myc and bcl6 rearrangements, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent nodal marginal zone lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory high grade b-cell lymphoma with myc and bcl2 rearrangements, refractory high grade b-cell lymphoma with myc and bcl6 rearrangements, refractory high grade b-cell lymphoma, not otherwise specified, refractory nodal marginal zone lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma